GlaxoSmithKline Reaches New 12-Month High at $54.20 (GSK)
GlaxoSmithKline (NYSE:GSK)’s share price reached a new 52-week high during trading hours on Friday, Stock Ratings News reports. The company traded as high as $54.20 and last traded at $54.02, with a volume of 1,848,980 shares traded. The stock had previously closed at $53.68.
Several analysts have recently commented on the stock. Analysts at UBS AG initiated coverage on shares of GlaxoSmithKline in a research note to investors on Thursday, January 9th. They set a “neutral” rating on the stock. Separately, analysts at Zacks reiterated a “neutral” rating on shares of GlaxoSmithKline in a research note to investors on Friday, December 20th. They now have a $54.00 price target on the stock. Finally, analysts at Deutsche Bank downgraded shares of GlaxoSmithKline from a “buy” rating to a “hold” rating in a research note to investors on Tuesday, December 17th. Three equities research analysts have rated the stock with a sell rating, nine have issued a hold rating and five have issued a buy rating to the stock. The stock presently has an average rating of “Hold” and a consensus price target of $104.00.
GlaxoSmithKline has a 52-week low of $43.68 and a 52-week high of $54.00. The stock’s 50-day moving average is $52.36 and its 200-day moving average is $51.7. The company has a market cap of $130.2 billion and a price-to-earnings ratio of 21.17.
GlaxoSmithKline (NYSE:GSK) last issued its quarterly earnings data on Wednesday, October 23rd. The company reported $0.31 earnings per share for the quarter. The company had revenue of $10.09 billion for the quarter, compared to the consensus estimate of $10.31 billion. On average, analysts predict that GlaxoSmithKline will post $3.69 earnings per share for the current fiscal year.
GlaxoSmithKline plc (NYSE:GSK) is global healthcare group, which is engaged in the creation and discovery, development, manufacture and marketing of pharmaceutical products, including vaccines, over-the-counter (OTC) medicines and health-related consumer products.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.